Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COR
COR logo

COR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cencora Inc (COR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
327.560
1 Day change
1.61%
52 Week Range
377.540
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cencora Inc (COR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive hedge fund activity, and favorable analyst ratings outweigh the lack of immediate trading signals and the neutral technical indicators.

Technical Analysis

The technical indicators are mixed. The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is neutral at 54.106, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 320.551, with resistance at 324.963 and support at 316.139.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • Hedge funds are heavily buying the stock, with a 2472.49% increase in buying activity last quarter.

  • Strong financial performance in Q1 2026, with revenue up 5.45% YoY, net income up 14.54% YoY, and EPS up 14.80% YoY.

  • Analysts maintain favorable ratings, with multiple upgrades and price target increases, reflecting optimism about the company's growth and strategic initiatives.

Neutral/Negative Catalysts

  • Lack of recent news or event-driven catalysts.

  • Neutral insider trading activity, with no significant trends in the past month.

  • Mixed technical indicators, with bearish moving averages and neutral RSI.

Financial Performance

Cencora Inc reported strong financials in Q1 2026. Revenue increased by 5.45% YoY to $85.93 billion, net income rose by 14.54% YoY to $559.65 million, EPS grew by 14.80% YoY to 2.87, and gross margin improved by 17.63% YoY to 3.27%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally positive on Cencora. Recent upgrades include Morgan Stanley and Jefferies, with price targets ranging from $360 to $440. Evercore ISI and Barclays also maintain Outperform and Overweight ratings, respectively, despite slight price target reductions. Analysts highlight the company's leadership in specialty distribution, international turnaround, and multi-year growth tailwinds.

Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
Wall Street analysts forecast COR stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 322.370
sliders
Low
400
Averages
415.38
High
440
Current: 322.370
sliders
Low
400
Averages
415.38
High
440
Evercore ISI
Outperform
to
Outperform
downgrade
$420 -> $360
AI Analysis
2026-04-08
Reason
Evercore ISI
Price Target
$420 -> $360
AI Analysis
2026-04-08
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on Cencora to $360 from $420 and keeps an Outperform rating on the shares. The firm made several price target adjustments and additions to the firm's Tactical call lists as part of the firm's healthcare technology and distribution preview for Q1.
BofA
Allen Lutz
Neutral
maintain
$360 -> $380
2026-03-06
Reason
BofA
Allen Lutz
Price Target
$360 -> $380
2026-03-06
maintain
Neutral
Reason
BofA analyst Allen Lutz raised the firm's price target on Cencora (COR) to $380 from $360 and keeps a Neutral rating on the shares. McKesson (MCK) "quietly" received a new National Drug Code for a biosimilar version of Neulasta a few weeks ago and while investors may be skeptical of McKesson's ambitions here, the firm frames "why this initial investor reaction could be wrong" based on seven large biosimilars coming to market over the next few years, including four that are directly addressable. The firm raised its McKesson target to reflect optionality on co-manufacturing and raised its Cencora (COR) target as well to reflect similar optionality.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COR
Unlock Now

People Also Watch